Product Code: RP-ID-10085833 |
Published Date: 21 Mar 2025 |
Region: Country |
Category: Healthcare & Pharmaceuticals |
Report ID: 10085833
Market Overview:
Q Fever Market Segmentation by Treatment (Surgery, and Antibiotic); by Type (Chronic, and Acute); and by Diagnosis (Serology Tests, and Others)-Global Demand Analysis & Opportunity Outlook 2031
Global Q Fever Market Highlights Over 2022 - 2031
The global Q fever market is estimated to grow at a ~8% CAGR over the forecast period, i.e., 2022 – 2031. Moreover, the market registered a notable revenue in 2021. The growth of the market can be attributed to the high prevalence of Q fever within the population and the increase in the percentage of the population engaged with animals for performing operations in agriculture. According to the World Bank, the development in agriculture is expected to feed approximately 9.7 million people by the end of 2050. Therefore, more people are expected to engage in the agriculture sector and come in contact with animals. In addition, the aged population percentage is increasing across the globe, that have a greater chance of being affected by diseases. Therefore, it is expected to drive the growth of the global Q fever market.
GET A SAMPLE COPY OF THIS REPORT
The global Q fever market is segmented by type into chronic and acute. Out of these, the chronic segment is anticipated to hold the largest share over the forecast period in the global Q fever market owing to the increase in the number of people dying from chronic diseases. Furthermore, it can harm the liver, brain, lungs, and heart and has a high prevalence across the globe.
Global Q Fever Market Regional Synopsis
Regionally, the global Q fever market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. On the strength of increasing awareness related to Q fever, rising care facilities for pets, and increasing advanced technologies for treatment, the North America region is anticipated to hold the largest share over the forecast period. Moreover, the market in the Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of the increase in the aged population that is more prone to diseases as compared to the younger population owing to low immunity. As per the World Bank, 26 percent of China’s total population is expected to be 65 or above and approximately 8 percent above 80 or above by the end of 2050. Moreover, there has been a high prevalence of disease that is expected to surge the growth of the Q market in the Asia Pacific region.
Market Segmentation
Our in-depth analysis of the global Q fever market includes the following segments:
By Treatment
-
Surgery
-
Antibiotic
By Type
-
Chronic
-
Acute
By Diagnosis
-
Serology Tests
-
Others
Growth Drivers and Challenges Impacting the Growth of the Global Q Fever Market
Growth Drivers
-
High prevalence of Q fever among the population
-
Increase in the percentage of the population in the agriculture sector
Challenges
-
Lack of awareness related to Q fever
-
High cost of Q fever treatment
Key Companies Dominating the Global Q Fever Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global Q fever market that are included in our report are Bayer AG, Merck KGaA, Melinta Therapeutics LLC, Basilea Pharmaceutica Ltd., Teva Pharmaceutical Industries Ltd., Sanofi-aventis U.S. LLC, Pfizer Inc., Yashica Pharmaceuticals Pvt. Ltd, Johnson & Johnson Services, Inc., Novartis AG, and others.
Latest Developments in the Global Q Fever Market:
-
6 November 2020: Basilea Pharmaceutica Ltd. announced its partner Shenzhen China Resources Gosun Pharmaceuticals Co. Ltd., received a drug approval license in China from National Medical Products Administration for Basilea’s antibiotic Zevtera.
-
6 April 2022: Melinta Therapeutics LLC announced its agreement with New American Therapeutics Inc., to acquire the U.S. right to TOPROL-XL and its Authorized Generic.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis, and challenges that impact market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessments for overall growth.
-
We provide customized reports as per the client's requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
- Bayer AG
- Merck KGaA
- Melinta Therapeutics LLC
- Basilea Pharmaceutica Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sanofi-aventis U.S. LLC
- Pfizer Inc.
- Yashica Pharmaceuticals Pvt. Ltd
- Johnson & Johnson Services Inc.
- Novartis AG,
Related Reports
Proof of Quality & Reliability
